A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

November 14, 2024

Study Completion Date

February 24, 2025

Conditions
Hemophilia B with InhibitorHemophilia B
Interventions
DRUG

SerpinPC

Administered as SC injection.

Trial Locations (20)

407

Taichung Veterans General Hospital, Taichung

2050

Royal Prince Alfred Hospital, Camperdown

3004

The Alfred Hospital, Melbourne

20122

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan

27834

East Carolina University, Greenville

28046

Hospital Universitario La Paz, Madrid

33612

University of South Florida, Tampa

34093

Istanbul University Oncology Institute, Istanbul

35100

Ege University Medical Faculty Hospital, Izmir

40201

Chung Shan Medical University, Taichung

40447

China Medical University Hospital, Taichung

59000

CHRU de Lille Centre de biologie et pathologie, Lille

60596

University Hospital Frankfurt M, Frankfurt

69500

Hospices Civils de Lyon (HCL) - Hopital Femme-Mere-Enfant (HFME), Lyon

75015

Hopital Necker - Enfants Malades, Paris

94270

Hopital Bicetre, Le Kremlin-Bicêtre

400022

K J Somaiya Super Speciality Hospital & Research Centre, Mumbai

80045-7202

University of Colorado School of Medicine, Aurora

0014

Centre of Haematology named after prof. R. O. Yeolian/ Hemophilia center, Yerevan

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Centessa Pharmaceuticals plc

INDUSTRY

lead

ApcinteX Ltd

INDUSTRY

NCT05789537 - A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors | Biotech Hunter | Biotech Hunter